A Phase 3, Open-Label, Single-Arm Study To Assess The Safety Of Hydromorphone Hydrochloride Delivered By Intrathecal Administration
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Hydromorphone (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors CNS Therapeutics; Mallinckrodt Inc.
- 28 Mar 2017 Planned End Date changed from 1 Dec 2017 to 1 Sep 2017.
- 28 Mar 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Sep 2017.
- 18 Oct 2016 Status changed from recruiting to active, no longer recruiting.